SCHEMBL4350295

SCHEMBL4350295

Cc1ccc(CNC2=NC(=O)C(=Cc3cccc(Oc4ccccc4)c3)S2)cc1

nearest known ligand 0.52

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 8/20 0.52
ADAMTS5 Q9UNA0 1/20 0.48
AKR1B1 P15121 4/20 0.46
MMP3 P08254 2/20 0.44
MMP13 P45452 2/20 0.44
PTPN1 P18031 4/20 0.43
ACP1 P24666 2/20 0.43
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4350290 1.00 ALOX5 (0.52) ALOX5ADAMTS5AKR1B1MMP3MMP13
SCHEMBL4348499 0.91 ALOX5 (0.54) ALOX5AKR1B1MMP3MMP13PTPN1
SCHEMBL4348504 0.91 ALOX5 (0.54) ALOX5AKR1B1MMP3MMP13PTPN1
SCHEMBL4351250 0.87 ADAMTS5 (0.51) ALOX5ADAMTS5AKR1B1MMP3MMP13
SCHEMBL4351246 0.87 ADAMTS5 (0.51) ALOX5ADAMTS5AKR1B1MMP3MMP13
SCHEMBL4350510 0.83 ALOX5 (0.49) ALOX5PTPN1ACP1ALDH1A1LMNA
SCHEMBL4350505 0.83 ALOX5 (0.49) ALOX5PTPN1ACP1ALDH1A1LMNA
SCHEMBL4350346 0.80 ALOX5 (0.51) ALOX5AKR1B1ALDH1A1LMNAMAPT
SCHEMBL4350344 0.80 ALOX5 (0.51) ALOX5AKR1B1ALDH1A1LMNAMAPT
SCHEMBL4355527 0.78 ALOX5 (0.51) ALOX5ADAMTS5AKR1B1MMP3MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP claimed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 ALOX5 2623/4885ADAMTS5 145/4885AKR1B1 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.